Current through Register Vol. 48, No. 38, September 20, 2024
a) The licensee in possession of any sealed
source shall assure that:
1) Each sealed
source, except as specified in subsection (b) of this Section, is tested for
leakage or contamination and the test results that confirm that the sealed
source is not leaking or contaminated are received before the sealed source is
put into use, unless the licensee has a certificate from the transferor
indicating that the sealed source was tested within 6 months for beta and gamma
emitting sources, or within 3 months for sources designed to emit alpha
particles, before transfer to the licensee.
2) Each sealed source that is not designed to
emit alpha particles is tested for leakage or contamination at intervals not to
exceed 6 months or at alternative intervals approved by the Agency, pursuant to
32 Ill. Adm. Code
330.280(m),
the U.S. Nuclear Regulatory Commission, an Agreement State or a Licensing
State.
3) Each sealed source that
is designed to emit alpha particles is tested for leakage or contamination at
intervals not to exceed 3 months or at alternative intervals approved by the
Agency, pursuant to 32 Ill. Adm. Code
330.280(m),
the U.S. Nuclear Regulatory Commission, an Agreement State or a Licensing
State.
4) Each sealed source that
is required to be tested for leakage or contamination shall be removed from
service if there is reason to suspect that the sealed source may have been
damaged or may be leaking or contaminated. The source shall be kept out of
service until test results that confirm there is no leakage or contamination
are received.
5) Tests for leakage
for all sealed sources, except brachytherapy sources manufactured to contain
radium, shall be capable of detecting the presence of 185 Bq (0.005 µCi)
of radioactive material on a test sample. Test samples shall be taken from the
sealed source or from the surfaces of the container in which the sealed source
is stored or mounted on which one might expect contamination to accumulate. For
a sealed source contained in a device, test samples shall be obtained when the
source is in the "off" position. If setting the source to the "off" position
would disrupt the licensee's activities, test samples may be obtained while the
source is in the "on" position, provided that the dose likely to be received by
the individual while obtaining the samples will not be so great as to require
monitoring pursuant to Section
340.520(a)
of this Part.
6) The test for
leakage for brachytherapy sources manufactured to contain radium shall be
capable of detecting an absolute leakage rate of 37 Bq (0.001 µCi) of
radon-222 in a 24 hour period when the collection efficiency for radon-222 and
its daughters has been determined with respect to collection method, volume and
time.
7) Tests for contamination
from radium daughters shall be taken on the interior surface of brachytherapy
source storage containers and shall be capable of detecting the presence of 185
Bq (0.005 µCi) of a radium daughter which has a half-life greater than 4
days.
b) A licensee need
not perform tests for leakage or contamination on the following sealed sources:
1) Sealed sources containing only radioactive
material with a half-life of less than 30 days;
2) Sealed sources containing only radioactive
material as a gas;
3) Sealed
sources containing 3.7 MBq (100 µCi) or less of beta or photon emitting
material or 370 kBq (10 µCi) or less of alpha emitting
material;
4) Sealed sources
containing only hydrogen-3;
5)
Seeds of iridium-192 encased in nylon ribbon;
6) Sealed sources, except teletherapy and
brachytherapy sources, that are stored, not being used and identified as in
storage. The licensee shall, however, test each such sealed source for leakage
or contamination and receive the test results that confirm that the sealed
source is not leaking or contaminated before any use or transfer unless it has
been tested for leakage or contamination within 6 months for beta and gamma
emitting sources, or within 3 months for sources designed to emit alpha
particles, before the date of use or transfer; and
7) Sealed sources distributed under a license
issued pursuant to 32 Ill. Adm. Code
330.280(m),
but only if the evaluation sheet for those sealed sources, as filed in the
"Radioactive Material Reference Manual" maintained by the Department of Health
and Human Services or in the "Registry of Radioactive Sealed Sources and
Devices" maintained by the U.S. Nuclear Regulatory Commission, specifies that
testing for leakage or contamination is not required.
c) Tests for leakage or contamination from
sealed sources shall be performed by persons specifically authorized by the
Agency, an Agreement State, a Licensing State or the Nuclear Regulatory
Commission to perform such services.
d) Test results shall be kept as specified in
Section
340.1135
of this Part.
e) The following
shall be considered evidence that a sealed source is leaking:
1) The presence of 185 Bq (0.005 µCi)
or more of removable contamination on any test sample.
2) Leakage of 37 Bq (0.001 µCi) of
radon-222 per 24 hours for brachytherapy sources manufactured to contain
radium.
3) The presence of
removable contamination resulting from the decay of 185 Bq (0.005 µCi) or
more of radium.
f) The
licensee shall immediately withdraw a leaking or contaminated sealed source
from use and shall take action to prevent the spread of contamination. The
leaking or contaminated sealed source shall be repaired, decontaminated or
disposed of in accordance with this Part.
g) Reports of test results for leaking or
contaminated sealed sources shall be made pursuant to Section
340.1260
of this Part.